Corrigendum to “Second generation direct-acting antivirals – do we expect major improvements?”

Jordan J. Feld1,*, Graham R. Foster2,***

1Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, Canada; 2Queen Mary University London, London, UK

It has come to our attention that an error was made in the section entitled “Next generation DAAs in development for specific populations – Chronic kidney disease”. The article reads:

“The second generation protease inhibitor ABT-493 and NS5A inhibitor ABT-530 are also **renally cleared** and are active against all genotypes, including genotype 3(52), holding promise that non-sofosbuvir-based regimens safe in patients with CKD will be available in the relatively near future.”

However, this sentence should state:

“The second generation protease inhibitor ABT-493 and NS5A inhibitor ABT-530 are also **hepatically cleared** and are active against all genotypes, including genotype 3(52), holding promise that non-sofosbuvir-based regimens safe in patients with CKD will be available in the relatively near future.”

The authors would like to apologise for this error and any subsequent inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.jhep.2016.07.007.

* Corresponding authors. Addresses: Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University Health Network, University of Toronto, 200 Elizabeth Street, 9EN, M5G 2C4, Canada. Tel.: +1 6476387925; fax: +1 4166035472 (J.J. Feld), or Queen Mary University of London, The Blizard Institute, 4 Newark Street, London E1 4AT, UK. Tel.: +44 207 882 7242; fax: +44 207 882 2191 (G.R. Foster).

E-mail addresses: jordan.feld@uhn.ca (J.J. Feld), g.r.foster@qmul.ac.uk (G.R. Foster).